Zepbound wins in weight loss duel

13 May 2025

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and - in data presented by Eli Lilly (NYSE: LLY) - they have gone up against one another.

Lilly has announced detailed results from SURMOUNT-5, a Phase IIIb open-label clinical trial, evaluating the safety and efficacy of its own Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Novo Nordisk’s (NOV: N) Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes.

 At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to Wegovy across the trial. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical